108 related articles for article (PubMed ID: 30782837)
1. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
[TBL] [Abstract][Full Text] [Related]
2. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
[TBL] [Abstract][Full Text] [Related]
3. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
5. SPRED1 deletion confers resistance to MAPK inhibition in melanoma.
Ablain J; Liu S; Moriceau G; Lo RS; Zon LI
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33306107
[TBL] [Abstract][Full Text] [Related]
6. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
Wu M; Hanly A; Gibson F; Fisher R; Rogers S; Park K; Zuger A; Kuang K; Kalin JH; Nocco S; Cole M; Xiao A; Agus F; Labadorf A; Beck S; Collard M; Cole PA; Alani RM
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38300709
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor is a determinant of melanoma targeted drug resistance.
Samarkina A; Youssef MK; Ostano P; Ghosh S; Ma M; Tassone B; Proust T; Chiorino G; Levesque MP; Goruppi S; Dotto GP
Nat Commun; 2023 Oct; 14(1):6498. PubMed ID: 37838724
[TBL] [Abstract][Full Text] [Related]
8. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.
Giricz O; Mo Y; Dahlman KB; Cotto-Rios XM; Vardabasso C; Nguyen H; Matusow B; Bartenstein M; Polishchuk V; Johnson DB; Bhagat TD; Shellooe R; Burton E; Tsai J; Zhang C; Habets G; Greally JM; Yu Y; Kenny PA; Fields GB; Pradhan K; Stanley ER; Bernstein E; Bollag G; Gavathiotis E; West BL; Sosman JA; Verma AK
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046005
[TBL] [Abstract][Full Text] [Related]
9. Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Sale MJ; Minihane E; Monks NR; Gilley R; Richards FM; Schifferli KP; Andersen CL; Davies EJ; Vicente MA; Ozono E; Markovets A; Dry JR; Drew L; Flemington V; Proia T; Jodrell DI; Smith PD; Cook SJ
Nat Commun; 2019 Nov; 10(1):5167. PubMed ID: 31727888
[TBL] [Abstract][Full Text] [Related]
10. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.
Smith MP; Sanchez-Laorden B; O'Brien K; Brunton H; Ferguson J; Young H; Dhomen N; Flaherty KT; Frederick DT; Cooper ZA; Wargo JA; Marais R; Wellbrock C
Cancer Discov; 2014 Oct; 4(10):1214-1229. PubMed ID: 25256614
[TBL] [Abstract][Full Text] [Related]
11. BOP1 Promotes Prostate Cancer through the DUSP6/MAPK Pathway.
Wu X; Jing Z; Huang T; Jing Y
Arch Esp Urol; 2023 Aug; 76(6):445-453. PubMed ID: 37681336
[TBL] [Abstract][Full Text] [Related]
12. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma.
Aya F; Lanuza-Gracia P; González-Pérez A; Bonnal S; Mancini E; López-Bigas N; Arance A; Valcárcel J
Cell Rep; 2024 Apr; 43(4):114048. PubMed ID: 38614086
[TBL] [Abstract][Full Text] [Related]
13. Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.
Li B; Kong X; Post H; Raaijmakers L; Peeper DS; Altelaar M
J Proteome Res; 2021 Sep; 20(9):4381-4392. PubMed ID: 34343000
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma.
Christodoulou E; Rashid M; Pacini C; Droop A; Robertson H; Groningen TV; Teunisse AFAS; Iorio F; Jochemsen AG; Adams DJ; Doorn RV
Pigment Cell Melanoma Res; 2021 Jan; 34(1):122-131. PubMed ID: 32767816
[TBL] [Abstract][Full Text] [Related]
15. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF
Schreck KC; Morin A; Zhao G; Allen AN; Flannery P; Glantz M; Green AL; Jones C; Jones KL; Kilburn LB; Nazemi KJ; Samuel D; Sanford B; Solomon DA; Wang J; Pratilas CA; Nicolaides T; Mulcahy Levy JM
Clin Cancer Res; 2021 Nov; 27(22):6197-6208. PubMed ID: 34433654
[TBL] [Abstract][Full Text] [Related]
16. ARID1A loss activates MAPK signaling via DUSP4 downregulation.
Mandal J; Yu ZC; Shih IM; Wang TL
J Biomed Sci; 2023 Dec; 30(1):94. PubMed ID: 38071325
[TBL] [Abstract][Full Text] [Related]
17. CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma.
Torres GM; Jarnagin HC; Park C; Yang H; Kosarek NN; Bhandari R; Wang CY; Kolling FW; Whitfield ML; Turk MJ; Liby KT; Pioli PA
bioRxiv; 2023 Aug; ():. PubMed ID: 37577680
[TBL] [Abstract][Full Text] [Related]
18. Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of
DuBose E; Bevill SM; Mitchell DK; Sciaky N; Golitz BT; Dixon SAH; Rhodes SD; Bear JE; Johnson GL; Angus SP
Front Oncol; 2024; 14():1191217. PubMed ID: 38854737
[TBL] [Abstract][Full Text] [Related]
19. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
20. CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance.
Gautron A; Bachelot L; Aubry M; Leclerc D; Quéméner AM; Corre S; Rambow F; Paris A; Tardif N; Leclair HM; Marin-Bejar O; Coulouarn C; Marine JC; Galibert MD; Gilot D
EMBO Mol Med; 2021 May; 13(5):e13466. PubMed ID: 33724679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
